887475-39-0

Usage

Uses

Used in Medicinal Chemistry and Pharmaceuticals:
3-Bromo-8-(methylthio)imidazo[1,2-a]pyrazine is utilized as a building block for the synthesis of various biologically active molecules. Its unique structural features contribute to the creation of compounds with potential therapeutic applications.
Used in Organic Synthesis:
3-BroMo-8-(Methylthio)iMidazo[1,2-a]pyrazine serves as a reagent in organic synthesis, facilitating the formation of new chemical entities that can be further explored for their properties and potential uses.
Used in Chemical Research:
3-Bromo-8-(methylthio)imidazo[1,2-a]pyrazine is employed as a research tool in the study of chemical reactions, providing insights into reaction mechanisms and the behavior of similar heterocyclic compounds in various chemical processes.

Upstream product

• 143591-61-1 3-bromo-8-chloro-imidazo[1,2-a]pyrazine 
• 5188-07-8 sodium thiomethoxide 
• 936361-36-3 3,8-dibromo-imidazo[1,2-a]pyrazine 
• 1263420-83-2 8-(methylthio)imidazo[1,2-a]pyrazine 
• 69214-33-1 8-chloroimidazo[1,2-α]pyrazine 

Downstream Products

• 1231257-87-6 acetic acid (3-(8-(methylthio)imidazo[1,2-a]pyrazin-3-yl)phenyl)amide 
• 1263420-84-3 methyl 4-(8-(methylthio)imidazo[1,2-a]pyrazin-3-yl)benzoate 
• 1263420-63-8 N-cyclopropyl-4-(8-((tetrahydro-2H-pyran-4-yl)methylamino)imidazo[1,2-a]pyrazin-3-yl)benzamide 
• 1263425-45-1 4-(8-(methylthio)imidazo[1,2-a]pyrazin-3-yl)benzoic acid 
• 1263420-67-2 N-cyclopropyl-4-(8-(methylthio)imidazo[1,2-a]pyrazin-3-yl)benzamide 
• 1263420-64-9 N-cyclopropyl-4-(8-(methylsulfonyl)imidazo[1,2-a]pyrazin-3-yl)benzamide 
• 1263420-65-0 N-Cyclopropyl-4-(8-((tetrahydro-2H-pyran-4-yl)methoxy)imidazo[1,2-a]pyrazin-3-yl)benzamide 
• 1263420-74-1 4-(8-(isobutylamino)imidazo[1,2-a]pyrazin-3-yl)-N-isopropylbenzamide 
• 1263420-69-4 N-cyclobutyl-4-(8-(isobutylamino)imidazo[1,2-a]pyrazin-3-yl)benzamide 
• 1263420-68-3 N-cyclopropyl-4-{8-(isobutylamino)imidazo[1,2-a]pyrazin-3-yl}benzamide 
• 1263421-11-9 N-cyclopropyl-4-(8-((thiophen-2-ylmethyl)amino)imidazo[1,2-a]pyrazin-3-yl)benzamide 
• 1263420-90-1 N-cyclopropyl-4-(8-(cyclopropylmethylamino)imidazo[1,2-a]pyrazin-3-yl)benzamide 
• 1263420-95-6 4-(8-(benzylamino)imidazo[1,2-a]pyrazin-3-yl)-N-cyclopropylbenzamide 
• 1263421-37-9 N-cyclopropyl-4-(8-(isopropylamino)imidazo[1,2-a]pyrazin-3-yl)benzamide 

Relevant academic research and scientific papers

FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION

Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR1—, ═N—, —CR7═), (—CR2═, ═N—, ═N—, —CR7═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NRA—, etc.; Z is a group represented by the formula —NR3R4 or a group represented by the formula —OR5; R1 to R3, R6, and R7 each is a hydrogen atom, etc.; R4 and R5 each is an (un)substituted alkyl, etc.; and R8 is an (un)substituted cycloalkyl, etc.

IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I) : in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Compounds of formula (I): wherein R1, R2, X1, and X2 are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.

Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors

The synthesis and structure-activity relationships (SAR) of novel, potent imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors are described. The X-ray crystal structure of imidazo[1,2-a]pyrazine Aurora inhibitor 1j is disclosed. Compound 10i was identified as lead compound with a promising overall profile.

IMIDAZOPYRAZINE COMPOUNDS

Novel imidazopyrazine compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.

Imidazopyrazines as protein kinase inhibitors

In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.